Get started
Novo Nordisk A/S
Long

NVO - buying quality compounder during panic

By humorousBear52981
Financials great, P/E 20 is very reasonable. Top line 20%+, LLY competition threats seems exaggerated. Last time was this oversold in 2017 and quickly rebounded. Impossible to replicate knowledge and ability to innovate. Started entry position at 78.5, will be DCA until it finds the bottom (if not already)

Happy weekend
Fundamental AnalysisTechnical Indicators
humorousBear52981

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.